ArticleFrontiers in oncology2026
Durable progression-free survival with first-line sintilimab plus chemotherapy followed by sintilimab maintenance in PD-L1-high recurrent cervical cancer: a case report.
Juan Liu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.